Americans Are Microdosing Obesity Drugs, Driven by 'Thin Is In' Marketing Blitz

Key Concepts

• GLP-1 Receptor Agonists: A class of weight-loss drugs, including Ozempic and Wegovy, originally developed for people with obesity or diabetes.
• Compounding Pharmacies: Pharmacies that prepare customized medications based on a doctor's prescription, often creating versions of existing drugs.
• Off-Label Prescribing: Prescribing a medication for a condition or patient group not specifically approved by regulatory bodies like the FDA.
• Telehealth Companies: Healthcare providers that offer medical services remotely, often through online platforms and apps.
• Diet Culture: Societal norms and beliefs that promote thinness as the ideal body type and often encourage restrictive eating habits.

Rise of Companies Around Weight Loss Drugs

The popularity of weight loss drugs, particularly GLP-1 receptor agonists like Ozempic and Wegovy, has led to the growth of companies that have built their business models around these medications. A significant part of this ecosystem involves compounding pharmacies, which have profited by creating their own versions of these drugs.

Off-Label Use and Marketing Trends

There has been a dramatic increase in the off-label use of these powerful weight loss drugs. A study released in August found that off-label Ozempic prescriptions for individuals who are not obese, overweight, or diabetic grew from 3% in 2018 to 30% in 2023. Similarly, off-label Wegovy prescriptions rose to as high as 38%. This trend is fueled by telehealth companies that are actively marketing GLP-1s, often targeting individuals who may not have a medical need for them. Many people are reporting seeing ads for these drugs, even when they do not struggle with obesity, indicating a shift in marketing towards a "thin is in" mentality.

Pharmaceutical Giants vs. Telehealth Companies

Eli Lilly and Novo Nordisk are the original creators of these weight loss shots. When the drugs first came to market, there was a huge demand, leading to shortages. This scarcity created an opportunity for telehealth companies to rise by offering compounded versions. However, these compounded medications are not the same as the rigorously studied drugs sold by the original manufacturers. Now that the shortages have eased, there is a tension between the pharmaceutical giants and telehealth companies, with the latter attempting to retain market share by marketing their compounded versions.

Regulatory Challenges and Concerns

Pharmaceutical companies face strict regulations regarding how they market their drugs, with limitations on overemphasizing effectiveness. Telehealth companies, however, do not fall under the same regulatory scrutiny, allowing them to market more broadly. This has led to concerns among medical professionals about the proliferation of advertisements perpetuating diet culture and body image issues. Doctors generally do not recommend these drugs for individuals at a healthy weight due to unknown long-term risks. Potential side effects for anyone taking a GLP-1 can include severe nausea, vomiting, and gastrointestinal issues.

Legal and Regulatory Actions

The FDA has taken some action by sending warning letters to telehealth companies, urging them to cease certain marketing practices, but these have often lacked significant legal or regulatory enforcement. Eli Lilly and Novo Nordisk have also pursued legal action by suing some of these telehealth firms, though some lawsuits have been dismissed.

Future Outlook

The future of this situation hinges on the actions of the federal government. Pharmaceutical companies have long urged the FDA to intervene more forcefully regarding compounding and telehealth companies. However, significant action has yet to be taken, making this an area to watch closely.

Synthesis/Conclusion

The widespread marketing and off-label use of GLP-1 weight loss drugs by telehealth companies, often utilizing compounded versions, present a complex challenge. While these medications can be beneficial for those with obesity or diabetes, their promotion for aesthetic weight loss raises significant concerns about patient safety, regulatory oversight, and the perpetuation of unhealthy body image ideals. The ongoing legal battles and the lack of decisive regulatory action highlight the need for greater clarity and enforcement to protect public health.